Abiopharma

🔍 McBee Brannin (Executive)

Company: CoreWeave, Inc. (CRWV)

Report Date: 2026-03-23

Detailed Transactions and Holdings:

• Acquired 16,665 shares of Class A Common Stock (Direct)
  Date: 2026-03-23 | Code: C | equity_swap_involved: 0 | shares_owned_after: 16,665.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,246 shares of Class A Common Stock at $81.0557 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 14,419.00 | transaction_form_type: 4 | Footnotes: F3, F4, F2
• Sold 7,749 shares of Class A Common Stock at $81.8776 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,670.00 | transaction_form_type: 4 | Footnotes: F3, F5, F2
• Sold 1,967 shares of Class A Common Stock at $82.981 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,703.00 | transaction_form_type: 4 | Footnotes: F3, F6, F2
• Sold 3,162 shares of Class A Common Stock at $83.8088 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,541.00 | transaction_form_type: 4 | Footnotes: F3, F7, F2
• Sold 1,541 shares of Class A Common Stock at $84.7346 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F8, F2
• Acquired 6,250 shares of Class A Common Stock (Direct)
  Date: 2026-03-23 | Code: C | equity_swap_involved: 0 | shares_owned_after: 6,250.00 | transaction_form_type: 4 | Footnotes: F1, F9
• Sold 843 shares of Class A Common Stock at $81.0556 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,407.00 | transaction_form_type: 4 | Footnotes: F3, F4, F9
• Sold 2,906 shares of Class A Common Stock at $81.8777 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,501.00 | transaction_form_type: 4 | Footnotes: F3, F5, F9
• Sold 737 shares of Class A Common Stock at $82.981 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,764.00 | transaction_form_type: 4 | Footnotes: F3, F6, F9
• Sold 1,187 shares of Class A Common Stock at $83.8089 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 577.00 | transaction_form_type: 4 | Footnotes: F3, F7, F9
• Sold 577 shares of Class A Common Stock at $84.7347 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F8, F9
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-03-23 | Code: H | nature_of_ownership: Canis Major SM Trust | shares_owned_after: 54,000.00 | Footnotes: F10
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-03-23 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 1,800.00 | Footnotes: F11
• Sold 16,665 shares of Class B Common Stock (Derivative)
  Date: 2026-03-23 | Code: C | equity_swap_involved: 0 | shares_owned_after: 4,033,902.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F12, F2
• Sold 6,250 shares of Class B Common Stock (Derivative)
  Date: 2026-03-23 | Code: C | equity_swap_involved: 0 | shares_owned_after: 604,955.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F12, F9
• Holds 324,000 shares of Class B Common Stock (Derivative)
  Date: 2026-03-23 | Code: H | shares_owned_after: 324,000.00 | Footnotes: F1, F1, F1, F13
• Holds 108,600 shares of Class B Common Stock (Derivative)
  Date: 2026-03-23 | Code: H | shares_owned_after: 108,600.00 | Footnotes: F1, F1, F1, F14
• Holds 1,582,773 shares of Class B Common Stock (Derivative)
  Date: 2026-03-23 | Code: H | shares_owned_after: 1,582,773.00 | Footnotes: F1, F1, F1, F12, F2
• Holds 122,000 shares of Class B Common Stock (Derivative)
  Date: 2026-03-23 | Code: H | shares_owned_after: 122,000.00 | Footnotes: F1, F1, F1, F15
• Holds 263,795 shares of Class B Common Stock (Derivative)
  Date: 2026-03-23 | Code: H | shares_owned_after: 263,795.00 | Footnotes: F1, F1, F1, F12, F9

Footnotes:

• F1: Each share of Class B Common Stock is convertible into one share of the Issuer's Class A Common Stock at any time, at the election of the holder or automatically upon certain transfers, whether or not for value, or upon the occurrence of certain events or conditions described in the Issuer's Amended and Restated Certificate of Incorporation.
• F2: The reported securities are directly held by a grantor retained annuity trust, of which the reporting person is the sole trustee and beneficiary.
• F3: The reported transaction represents a sale effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2025.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.37 to $81.36, inclusive.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.37 to $82.36, inclusive.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.37 to $83.36, inclusive.
• F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.37 to $84.36, inclusive.
• F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.37 to $85.26, inclusive.
• F9: The reported securities are directly held by a grantor retained annuity trust, of which the reporting person's spouse is the sole beneficiary and trustee.
• F10: The reported securities are directly held by the Canis Major SM Trust (the "Canis Trust"), an irrevocable trust with a third-party trustee, of which the reporting person's minor child is beneficiary. The reporting person has the power to remove and replace the Canis Trust's trustee.
• F11: The reported securities are directly held of record by the reporting person's child.
• F12: For clarity, the reporting person and his spouse previously effected indirect transfers in a series of transactions exempt from reporting under Section 16 of the Exchange Act of 1934, as amended, pursuant to Rule 16a-13 thereof. As a result: (i) the direct ownership of the Canis Major 2025 GRAT was reduced by 1,582,773 shares of the Issuer's Class B Common Stock, with such shares now directly held by the Canis Major 2026 GRAT; and (ii) the direct ownership of the Canis Minor 2025 GRAT was reduced by 263,795 shares, with such shares now directly held by the Canis Minor 2026 GRAT. For avoidance of doubt, the totals reported in Column 5 of Table I reflect ownership after such transactions, as well as the other transactions reported herein.
• F13: The reported securities are directly held by the Canis Major 2024 Irrevocable Trust LLC of which the reporting person serves as manager.
• F14: The reported securities are directly held by the Canis Major 2025 Family Trust LLC, of which the reporting person serves as manager.
• F15: The reported securities are directly held by the Canis Minor 2025 Family Trust LLC, of which the reporting person serves as manager.
• REMARKS: This Form 4 is Part 2 of 2 for this reporting person. Transactions by the reporting person are continued on this Part 2.